Skip to main content
. Author manuscript; available in PMC: 2022 May 6.
Published in final edited form as: Leukemia. 2021 Nov 6;36(3):723–732. doi: 10.1038/s41375-021-01441-9

Figure 5. Changes in Th17s and Tregs with dFCR Treatment as shown with Mass Cytometry.

Figure 5.

A. Change in CD4+ RORγT+ cells over time in the entire population. B. Markers driving clustering for c15, a Th17 phenotype CD8. C. %Tregs at screen comparing patients with and without toxicity. * p≤ to 0.05; ** p≤ to 0.01.